Press Releases

SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today
March 16, 2023
Positive clinical results demonstrated in stable relapsing multiple sclerosis patients adjunctive to immunomodulatory   disease modifying therapy was previously reported Updated Visual Evoked Potential (VEP) findings provide evidence of improved information signaling from the eye to the brain’s
February 27, 2023